Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
New Ray Medicine International Holding Ltd. ( (HK:6108) ) has provided an update.
New Ray Medicine International Holding Ltd. reported an 87.1% increase in revenue for the year ended December 31, 2024, reaching approximately HK$93.9 million. Despite this growth, the company experienced a 10.9% decrease in gross profit and a 39.6% increase in net loss, amounting to approximately HK$31.0 million. The board did not recommend a final dividend for the year, and the company maintained a gearing ratio of zero. These financial results indicate challenges in cost management and profitability, impacting the company’s overall financial health and stakeholder confidence.
More about New Ray Medicine International Holding Ltd.
New Ray Medicine International Holding Ltd. is a company incorporated in Bermuda with limited liability, operating in the pharmaceutical industry. The company is involved in the distribution and sale of pharmaceutical products, focusing on expanding its market presence and improving its financial performance.
YTD Price Performance: 10.0%
Average Trading Volume: 2,191,214
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$73.56M
For detailed information about 6108 stock, go to TipRanks’ Stock Analysis page.